Navigation Links
Vermillion Reports Fourth Quarter and Full Year 2012 Results
Date:2/20/2013

company's board has formed a succession committee of independent directors to oversee the process of identifying and selecting a permanent CEO. It has also retained a leading executive search firm with experience in CEO transitions to advise the board on potential candidates.

Conference Call and Webcast
Vermillion will hold a conference call to discuss its fourth quarter and full year financial results later today, Wednesday, February 20, 2013 at 4:30 p.m. Eastern time. Vermillion's interim CEO Bruce A. Huebner will host the call, followed by a question and answer period.

Date: Wednesday, February 20, 2013
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-909-4761
International: 1-212-231-2934
Conference ID#: 21648726
Webcast: http://edge.media-server.com/m/p/e247e2q2/lan/en

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call through March 6, 2013.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21648726

About OVA1
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.(1) In addition, OVA
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Vermillion Reports Second Quarter 2012 Results
6. Vermillion to Present at the 2012 Gateway Conference on September 6
7. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
8. Vermillion Reports Third Quarter 2012 Results
9. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
10. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
11. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... , August 3, 2015 BiondVax Pharmaceuticals ... statistical analysis of results from a study which demonstrates that ... II trial which took place in 2012, provided participants with ... the time of the study- in particular the current newly ... the United States in 2015. ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
(Date:8/3/2015)... ... ... opinion piece published July 28 by the Washington Post, the conventional wisdom that ... not be accurate. While this system may work for some people, the author notes that ... on the individual and at what point that person is in their weight loss journey. ...
(Date:8/3/2015)... ... , ... Bayer has agreed to pay $56.9 million to set up a ... to have suffered an arterial blood clot including stroke and heart attack. The litigation ... has been ongoing for well-over five years. In 2009, lawsuits filed against Bayer involving ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... contract research organisations (CROs) for a slew of benefits, allowing them to gain ... operations, boost quality with cost-effective utilisation of resources, get access to innovation and ...
(Date:8/3/2015)... ... 2015 , ... A recent survey by the National ... believe people can positively affect their diabetes, few look beyond diet changes to ... changes was important. Far fewer participants mentioned the need for exercise (30%), maintaining ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... for Provider Profiling, Predictive Modeling, Resource Management and ... DST Health Solutions today announced the ... DSTHS RiskAnalyzer(TM). RiskAnalyzer uses claims experience to determine ... under the Centers for Medicare and Medicaid Services ...
... QHR hospital clients received unexpected checks totaling nearly ... ranging from $65,000 to more than $750,000 - ... a unique and innovative partnership between the hospital ... Under the QHR/Gallagher Retro Insurance Program, hospital groups ...
... cadherin superfamily has a correlate relationship with the ... suggested that, unlike E-cadherin, N-cadherin may promote motility ... pathological significance of E-cadherin and N-cadherin expressions in ... led by Prof. Qing-Xia Fan from China detected ...
... 100,000 Swedes are under treatment with the blood-thinning drug ... makes the initiation of treatment a risky balancing act ... Uppsala University have developed a model for calculating the ... in the scientific publication New England Journal of ...
... PURCHASE, N.Y., Feb. 19 The PepsiCo Foundation ... Save the Children to help ensure the survival ... and Bangladesh, which together are home to 40 ... )With support from the PepsiCo Foundation, Save ...
... 19 Cardium Therapeutics (NYSE Alternext US: CXM) ... on January 23, 2009 has been accepted by ... Stock Exchange). (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO )As ... from the staff of its current listing exchange ...
Cached Medicine News:Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 2Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 3Health News:QHR, Gallagher Partnership Yields More Thank $4 Million for QHR Hospital Clients 2Health News:Knowledge of genetics improves uncertain medication 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 2Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 4Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 5
... use, the z-boxTM is designed to bring ... business model behind the z-boxTM is designed ... most flexible way to bring this technology ... to run procedure specific software in many ...
NOW Legionella is an immunochromatographic membrane assay to detect Legionella pneumophila serogroup 1 soluble antigen in human urine....
ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults....
... The BinaxNOW Influenza A & B ... easiest flu test on the market ... between influenza A and influenza B ... test. Now you can focus on ...
Medicine Products: